-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Optimizing Myelofibrosis Management With Current and Emerging Therapies

Sponsor: AbbVie, Bristol Myers Squibb, GSK, and Karyopharm Therapeutics
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Friday, December 8, 2023: 11:00 AM-2:00 PM
Marriott Grand Ballroom 8-9 (Marriott Marquis San Diego Marina)
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center
Bose: GSK, Novartis, Karyopharm, AbbVie, Pharma Essentia, Jubilant, Morphic: Honoraria; Kartos, Telios, Disc, Janssen, Geron: Research Funding; Incyte, BMS, CTI, Morphosys, Blueprint, Cogent, Sumitomo, Ionis: Honoraria, Research Funding.
Stephen T. Oh, MD, PhD, Washington University School of Medicine and Nikolai A. Podoltsev, MD, PhD, Yale School of Medicine
Oh: CTI BioPharma, Bristol Myers Squibb, Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation/MorphoSys, Geron, AbbVie, Sierra Oncology/GSK, Cogent, Incyte, Morphic, Protagonist: Consultancy. Podoltsev: AbbVie Inc.; Blueprint Medicines (former); Constellation Pharmaceuticals (former); CTI BioPharma Corp. (former); Incyte Corporation (former); Novartis (former); PharmaEssentia (former): Consultancy; AI Therapeutics; Arog Pharmaceuticals; Astellas Pharma, Inc.; Astex Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; CTI BioPharma Corp.; Daiichi Sankyo, Inc.; Genentech, Inc.; Jazz Pharmaceuticals, Inc.; Kartos Therapeuti: Research Funding; Cogent Biosciences: Other: IDMC Member.
On Demand program will be available here January 8, 2024.

This 90-minute symposium will present a comprehensive review of the recent updates related to current and emerging therapies in MF. Featuring a lively and engaging format resembling a talk show, 3 expert faculty in MF will discuss the evolving MF treatment paradigm. Discussion will review the current treatment landscape, emerging therapies, and practical management strategies to optimize patient outcomes.